Lou Silverman - 30 Nov 2022 Form 3 Insider Report for Oncocyte Corp (OCX)

Role: Director
Signature: /s/ Lou Silverman
Issuer symbol: OCX
Transactions as of: 30 Nov 2022
Net transactions value: $0
Form type: 3
Filing time: 09 Dec 2022, 19:21:27 UTC
Previous filing: 12 Aug 2021
Next filing: 27 Jun 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	OCX	Common Stock, no par value						6,270	30 Nov 2022	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	OCX	Option to Purchase Common Stock							30 Nov 2022	Common Stock	27,987	$0.4644	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Includes: (i) 50 shares of common stock, and (ii) 6,220 restricted stock units which shall vest on December 7, 2023, one year from the date of grant, subject to the Reporting Person's continued service as a director of the Issuer from the date of grant until the vesting date.
F2	Options shall vest one year from the date of grant, subject to the Reporting Person's continued service as a director of the Issuer from the date of grant until the vesting date.